Every Form 4 that Accendra Health, Inc. (ACH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACH filings page.
Accendra Health EVP and General Counsel Heath H. Galloway reported a routine tax-related share disposition. On May 18, 2026, 1,822 shares of Accendra Health common stock were surrendered at $2.91 per share to cover tax withholding tied to vesting of restricted stock.
These shares were delivered back to the company rather than sold in the open market. After this transaction, Galloway directly holds 166,306 shares of Accendra Health common stock, showing he retains a substantial equity stake following the tax withholding event.
Accendra Health EVP & CFO Jonathan A. Leon reported a small share disposition related to taxes rather than an open-market trade. On May 15, 2026, he surrendered 1,770 shares of Common Stock at $3.04 per share to cover tax withholding tied to vesting of restricted stock. After this tax-withholding transaction, he directly held 290,533 shares of Accendra Health common stock.
Accendra Health President and CEO Edward A. Pesicka surrendered 17,692 shares of common stock on May 15, 2026 to cover tax withholding obligations tied to vesting of restricted stock. These shares were delivered back to the company rather than sold on the open market. Following this routine tax-withholding disposition, he directly holds 1,072,785 common shares.
Accendra Health Inc. executive Heath H. Galloway reported a routine tax-related share disposition. On this Form 4, 966 shares of common stock were surrendered to the company at $3.04 per share to cover tax withholding tied to vesting of restricted stock. After this non-market transaction, Galloway directly holds 168,128 common shares.
Accendra Health Inc. executive Perry A. Bernocchi, EVP and Chief Operating Officer, reported a routine tax-related share disposition. On May 15, 2026, he surrendered 7,908 shares of common stock at $3.04 per share to cover tax withholding tied to vesting of restricted stock. After this non-market transaction, he directly holds 313,913 shares of Accendra Health common stock.
Kline Teresa L. reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Teresa L. Kline received a grant of 31,191 shares of common stock as equity compensation. The shares were awarded at no cash cost to her and are structured as restricted stock. Following this grant, she directly holds 85,316 common shares.
The restricted stock grant will vest on the earlier of one year from the grant date or the date of the next annual meeting that occurs at least 50 weeks after the grant date, aligning the director’s compensation with shareholder interests over that period.
Klemash Stephen W reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ director Stephen W. Klemash received a grant of 31,191 shares of Common Stock as a restricted stock award. The grant was awarded at a price of $0.00 per share as part of equity compensation and increased his directly held shares to 90,242.
The restricted stock will vest on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. This is a compensation-related equity grant rather than an open-market share purchase.
Gardner-Smith Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Kenneth Gardner-Smith received a grant of 31,191 shares of Common Stock as restricted stock on May 14, 2026. These shares were awarded at no cash cost and increase his direct holdings to 86,113 shares.
The restricted stock grant vests on the earlier of one year from the grant date or the next annual meeting that is at least 50 weeks after the grant date, meaning the award is tied to continued board service over roughly a one-year period.
Bingham Gwendolyn M reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health director Gwendolyn M. Bingham received a grant of 31,191 phantom stock units on May 14, 2026 at no cost. This award increases her phantom stock holdings to 80,603 units. Each phantom unit is convertible on a 1-for-1 basis into common stock and becomes payable, in cash or common stock at her election, upon events such as death, disability, termination of service as director, or a preselected future delivery date.
Beck Mark A reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Mark A. Beck received a grant of 31,191 shares of common stock as equity compensation. The restricted stock was awarded at no cash cost to him and increases his direct holdings to 71,259 shares.
According to the terms, the restricted stock vests on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. Until vesting, these shares are subject to forfeiture conditions typically linked to continued board service.
Accendra Health President & CEO Edward A. Pesicka reported a tax-related share disposition, not an open-market stock sale. On the Form 4, 58,945 shares of common stock were surrendered at $2.03 per share to cover tax withholding tied to vesting of restricted stock.
These shares were delivered back to the company rather than sold to outside investors. After this transaction, Pesicka directly holds 1,090,477 shares of Accendra Health common stock, indicating he retains a substantial equity position in the company.
ACCENDRA HEALTH INC/VA/ executive reports routine tax withholding share disposition. EVP & CFO Jonathan A. Leon surrendered 11,286 shares of common stock on 2026-03-20 to the company to cover tax withholding tied to vesting of restricted stock. This was not an open-market sale. After the transaction, he directly holds 292,303 shares of common stock.
Accendra Health executive Perry A. Bernocchi reported a routine tax-related share disposition. On March 20, 2026, he surrendered 20,841 shares of common stock at $2.03 per share to the company to satisfy tax withholding obligations tied to vesting restricted stock. This was not an open-market sale, and he still directly holds 321,821 shares after the transaction.
Accendra Health executive Heath H. Galloway transferred 9,347 shares of common stock to the company at $2.03 per share to cover tax withholding on vested restricted stock. This non‑market, tax-withholding disposition leaves him holding 169,094 shares directly, reflecting a routine compensation-related adjustment rather than an open-market trade.
Bernocchi Perry A reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health executive Perry A. Bernocchi, EVP and Chief Operating Officer, received a grant of 108,696 shares of Common Stock as equity compensation. The restricted stock grant vests one-third per year over three years. Following this award, his directly held stake totals 342,662 shares.
Leon Jonathan A reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ EVP & CFO Jonathan A. Leon received a grant of 85,067 shares of common stock. The shares are restricted stock that vest one-third per year over three years, meaning they become fully owned gradually over time. After this award, he directly holds 303,589 common shares. This is a compensation-related equity grant at no cash cost and does not involve any open-market buying or selling.
Galloway Heath H reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ granted EVP, General Counsel & Corporate Secretary Heath H. Galloway 61,437 shares of Common Stock as a restricted stock award. The grant carries no purchase price and vests one-third per year over three years. Following this compensation award, Galloway directly holds 178,441 Common Stock shares. This is a non-market, equity-based compensation grant rather than an open-market purchase or sale, so it reflects long-term incentive alignment more than a trading view on the stock.